Deleted Tweets From Scott Gottlieb, R-D.C.

This will enhance protection of human research subjects and reduce the regulatory burden on the research community by creating efficiencies and strengthening standards in the clinical trial enterprise https://t.co/IDTIja2J80

#FDA is committed to protecting safety of people who participate in clinical trials https://t.co/IfkLOhrK30 Today we issued guidance w/HHS describing consistent approach to written procedures implemented by institutions & IRBs responsible for oversigh

#FDA will continue to update the new website we unveiled today with new inquiries we receive from generic manufacturers who identify to us that they are having difficulty accessing samples of branded drugs to conduct generic registration studies https://t

I want to thank @statnews for correcting the earlier version of their story on right to try by @ikeswetlitz that mischaracterized parts of our discussion; we appreciate the publication’s responsiveness

.@FDATobacco is planning consumer perception study to further inform its evaluation of potential modified risk tobacco products (MRTP). How the public understands the relative risk of tobacco-related disease is an important element of MRTP review: https:/

UPDATE on Romaine Lettuce: It is highly unlikely that product from the Yuma growing region is still in the supply chain. Consumers can be confident that romaine currently available for purchase is not part of the investigation. FDA continues to investigat

RT @CNBC: The FDA gave expedited approval for the first non-opioid treatment to ease withdrawal from quitting addictive opioi… https://t.co/WxAlNcQQsY

RT @FDAOncology: Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada https://t.co/8Rr3kcUxLM

RT @NYTHealth: The F.D.A. begins outing drug makers it claims refuse to share drug samples for cheaper generic copies of big-name… https://t.co/6B0pgXvmrj

Encouraging development of innovative products that may be less dangerous than cigarettes for adults who still seek nicotine is a cornerstone of #FDA’s comprehensive plan on tobacco & nicotine. This study aims to inform reviews of these potential prod

https://t.co/6Fqv2gxWiH

https://t.co/dujk1FGDeK

The advances FDA will soon announce to the organization of its drug review process will, among other things, create many new review divisions that are focused on specific disease areas as a way to better focus our expertise and balance workload across CDE

RT @FDAOncology: Join us June 14 for the FDA-AACR-SGO Workshop on Drug Development in Gynecologic Malignancies, at FDA in Silver Spr… https://t.co/xFvmO6iCuN

#FDA will continue to call out scenarios where we think drug makers may be using tactics to unfairly delay generics. Patients deserve a market that fosters access to generics after lawful IP has lapsed on a brand drug https://t.co/4Liiu8m4w6 https://t.co/

RT @tmprowell: #Oncology fellows & fellowship program directors, interested in an 8 wk rotation w/ @FDAOncology? Learn more here: https://… QT @FDAOncology: The #FDAOncology Fellows Program is an 8-week rotation to learn about the role of FDA throughout all phases of onco… https://t.co/pYHL3dseMQ)

RT @SGottliebFDA: We’ll continue to take vigorous steps under #FDA’s Youth Tobacco Prevention Plan, using the full scope of our autho… https://t.co/8QDLVs46Vu

Part of the focus of these reforms will also be aimed at developing an integrated assessment of new drug applications that’ll create more internal collaboration across different #FDA scientific domains that contribute to drug review like statisticians, ph

The #FDA appreciates the funding increase approved by the House Appropriations Committee. It’ll help considerably in advancing #FDA public health priorities including working with Congress to combat opioid abuse and enhancing medical product innovation ht

By having review divisions focused on specific disease areas like liver disease or maternal health; it’ll give us more ability to expand our scientific leadership in different medical fields and focus more of our efforts on advancing guidance that can fac

This will enhance protection of human research subjects and reduce the regulatory burden on the research community by creating efficiencies and strengthening standards in the clinical trial enterprise https://t.co/IDTIja2J80

#FDA is committed to protecting safety of people who participate in clinical trials https://t.co/IfkLOhrK30 Today we issued guidance w/HHS describing consistent approach to written procedures implemented by institutions & IRBs responsible for oversigh

#FDA will continue to update the new website we unveiled today with new inquiries we receive from generic manufacturers who identify to us that they are having difficulty accessing samples of branded drugs to conduct generic registration studies https://t

I want to thank @statnews for correcting the earlier version of their story on right to try by @ikeswetlitz that mischaracterized parts of our discussion; we appreciate the publication’s responsiveness

.@FDATobacco is planning consumer perception study to further inform its evaluation of potential modified risk tobacco products (MRTP). How the public understands the relative risk of tobacco-related disease is an important element of MRTP review: https:/

UPDATE on Romaine Lettuce: It is highly unlikely that product from the Yuma growing region is still in the supply chain. Consumers can be confident that romaine currently available for purchase is not part of the investigation. FDA continues to investigat

RT @CNBC: The FDA gave expedited approval for the first non-opioid treatment to ease withdrawal from quitting addictive opioi… https://t.co/WxAlNcQQsY

RT @FDAOncology: Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada https://t.co/8Rr3kcUxLM

RT @NYTHealth: The F.D.A. begins outing drug makers it claims refuse to share drug samples for cheaper generic copies of big-name… https://t.co/6B0pgXvmrj

Encouraging development of innovative products that may be less dangerous than cigarettes for adults who still seek nicotine is a cornerstone of #FDA’s comprehensive plan on tobacco & nicotine. This study aims to inform reviews of these potential prod

https://t.co/6Fqv2gxWiH

https://t.co/dujk1FGDeK

The advances FDA will soon announce to the organization of its drug review process will, among other things, create many new review divisions that are focused on specific disease areas as a way to better focus our expertise and balance workload across CDE

RT @FDAOncology: Join us June 14 for the FDA-AACR-SGO Workshop on Drug Development in Gynecologic Malignancies, at FDA in Silver Spr… https://t.co/xFvmO6iCuN

#FDA will continue to call out scenarios where we think drug makers may be using tactics to unfairly delay generics. Patients deserve a market that fosters access to generics after lawful IP has lapsed on a brand drug https://t.co/4Liiu8m4w6 https://t.co/

RT @tmprowell: #Oncology fellows & fellowship program directors, interested in an 8 wk rotation w/ @FDAOncology? Learn more here: https://… QT @FDAOncology: The #FDAOncology Fellows Program is an 8-week rotation to learn about the role of FDA throughout all phases of onco… https://t.co/pYHL3dseMQ)

RT @SGottliebFDA: We’ll continue to take vigorous steps under #FDA’s Youth Tobacco Prevention Plan, using the full scope of our autho… https://t.co/8QDLVs46Vu

Part of the focus of these reforms will also be aimed at developing an integrated assessment of new drug applications that’ll create more internal collaboration across different #FDA scientific domains that contribute to drug review like statisticians, ph

The #FDA appreciates the funding increase approved by the House Appropriations Committee. It’ll help considerably in advancing #FDA public health priorities including working with Congress to combat opioid abuse and enhancing medical product innovation ht

By having review divisions focused on specific disease areas like liver disease or maternal health; it’ll give us more ability to expand our scientific leadership in different medical fields and focus more of our efforts on advancing guidance that can fac